Introduction
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus that establishes latency in greater than 90% of the human population. In immunocompetent hosts, latency is controlled by EBV-specific T cells that recognize primarily epitopes in the immunodominant latency III proteins EBV nuclear antigen (EBNA) 3A, 3B and 3C. 1, 2 However, EBV-positive nasopharyngeal carcinoma and Hodgkin lymphoma typically demonstrate latency II antigen expression, characterized by loss of most EBV antigens except for the latent membrane protein (LMP) 1 and 2 and the EBNA-1 protein. [3] [4] [5] It is difficult to generate effective antigen-specific T cells against latency II antigens due to poor immunogenicity. Recently, new in vitro stimulation protocols have been developed to facilitate the generation of LMP1-and LMP2-specific T-cell populations for adoptive therapy. 6, 7 In this study, we used an alternative approach and explored if TCR gene transfer can be used to reproducibly generate LMP2-specific cytotoxic T cells (CTL).
Retroviral transfer of TCR genes is an attractive strategy to redirect the antigen specificity of T cells. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] The feasibility of this strategy was recently demonstrated in the first clinical trial with TCR gene-modified T cells in melanoma patients. 23 However, there is now evidence that 'weak' TCR are poorly expressed upon retroviral transfer into human T cells, while 'strong' TCR are expressed at high levels. 24, 25 The molecular basis that determines TCR 'strength' is currently unknown, and it is also unclear if it is possible to turn a 'weak' TCR into a 'strong' TCR by modifying the retroviral expression construct.
In this study, we found that a TCR specific for an LMP2 peptide presented by human leukocyte antigen (HLA)-A2 behaved like a 'weak' TCR, being poorly expressed upon retroviral transfer into primary human T cells. In an attempt to generate a 'strong' TCR, we combined several strategies that were previously used to improve the expression of human TCR in primary T cells. First, we replaced the human constant region with murine sequences, which can enhance the TCR association with CD3 molecules and reduce mispairing with endogenous TCR chains. 26 Second, we linked the TCR a and b genes with the self-cleaving 2A sequence of porcine teschovirus in an attempt to obtain equimolar expression of both TCR chains. Finally, we codon optimized the genes to facilitate TCR mRNA translation in human T cells. 27 We show that these modifications converted the 'weak' TCR into a 'strong' TCR that was efficiently expressed and functionally active in human T cells. Although the benefit of the individual modifications has been previously described, we show here that combining these modifications produced a dominant TCR that prevented the surface expression of a large proportion of endogenous TCR in human T cells.
Results and discussion
For this study, we used a well-characterized TCR, specific for an LMP2-derived peptide presented by HLA-A2, which was isolated from an allorestricted CTL line (N Steven, manuscript in preparation). Recently, the structures of this TCR and the HLA-A2/ LMP2 complex have been resolved providing detailed insight into the molecular details of the TCR and its ligand (B Willcox, unpublished data).
The LMP2-TCR is poorly expressed in primary human T cells
Initially, we inserted the TCR a and b genes separately into the retroviral vector pMP71-PRE. This approach had been used in the past for efficient TCR expression in human T cells. 22 As a control, we used the two pMP71-PRE constructs containing the a and b genes of a TCR specific for an HLA-A2-presented peptide of Wilms' Tumour antigen 1 (WT1). 22 Retroviral transduction of human Jurkat 76 cells, which do not express endogenous TCR chains, demonstrated that the LMP2-TCR and the WT1-TCR were expressed in a similar percentage of cells at similar levels (Figures 1a and b) . However, differences were observed when the same retroviral supernatants were used to transduce primary human T cells. The Vb13.1 chain, used by the LMP2-TCR, was expressed in a relatively small percentage of the transduced CD8+ T cells, as only 2.5 % CD8+Vb13.1+ T cells were detectable after LMP2-TCR transduction, which included 1.9% CD8+ T cells expressing endogenous Vb13.1+ T cells as quantified in mock-transduced control cells (Figure 1c) . In contrast, the percentage of CD8+ T cells expressing the Vb2.1 chain of the WT1-TCR (8.1% CD8+Vb2.1+ T cells versus 2.3% in the mock-transduced control cells) indicated that this TCR was expressed more efficiently than the LMP2-TCR in primary human T cells chains were cloned separately into retroviral pMP71-PRE vectors. 22, 28 The HLA-A2-restricted WT1-specific TCR utilizes Va1.5 and Vb2.1. The a and b chains were inserted into separate pMP71-PRE vectors as described previously. 22 Phoenix amphotropic packaging cells were transfected with retroviral vector constructs using calcium phosphate precipitation (Invitrogen, Carlsbad, CA, USA). Medium was replaced 24 h later and the supernatant containing retroviral particles was harvested after a further 24 h incubation at 37 1C in 5% CO 2 . Jurkat 76 cells were split 24 h before transduction. Twenty-four-well cell culture plates (Greiner Bio One International, Munich, Germany) coated with retronectin (Takara, Otsu, Shiga, Japan) were seeded with 1 Â 10 6 cells in 1 ml Roswell Park Memorial Institute (RPMI) cell culture medium, incubated for 30 min and then transduced with 1 ml of retroviral supernatant. Cell culture medium was replaced after 24 h and supplemented with 100 U ml ( Figure 1d ). Poor expression of the wild-type LMP2-TCR was consistently observed in independent transduction experiments with peripheral blood lymphocytes. We proceeded to combine several strategies to explore if it is possible to produce a TCR construct that can outcompete the endogenous TCR chains for expression on the cell surface, thus improving the expression of the introduced LMP2-TCR. We selected three modifications to enhance the efficiency of TCR biosynthesis at different levels of the pathway. Codon optimization was used to enhance the translation of the LMP2-TCR mRNA, a strategy that was reported previously to enhance TCR expression. 27 The self-cleaving 2A sequence of porcine teschovirus 29 was used to obtain similar amounts of TCR a and b chain within each transduced cell, and finally, the murine constant region sequences were used to enhance the correct pairing and improve the assembly with CD3 molecules. 20, 26 
LMP2-TCR modifications improve expression in T cells
The modifications made to the TCR sequences and the retroviral vector configuration are shown schematically (Figure 2a) . Transduction of Jurkat 76 cells with the modified LMP2-TCR vector consistently resulted in highlevel CD3 and Vb13.1 expression (Figures 2b and c) . The transduced Jurkat 76 cells also stained with antibodies specific for the constant region of murine TCR b chain but not with antibodies against the human a/b TCR (Figures 2d and e) .
The transduction of primary human T lymphocytes demonstrated that the modified LMP2-TCR construct was efficiently expressed in cells despite competition with endogenous TCR chains. A large percentage of transduced T cells expressed the Vb13.1 chain of the LMP2-TCR and the level of expression, as determined by mean fluorescence intensity, was similar to that seen for endogenous Vb13.1 (Figures 2f and g ). Further analysis indicated that T cells expressing the modified LMP2-TCR stained with antibodies against the constant region of murine TCR b chain and a proportion of these cells also bound to HLA-A2/LMP2 pentamers (Figure 2h ). No pentamer staining was seen in the T cells that did not express the murine CB.
Previous studies of the LMP2-TCR used in this study have provided detailed biochemical and structural information (B Willcox, unpublished data). The TCR was isolated from an HLA-A2-restricted, LMP2-specific CTL line that was generated in vitro from peripheral blood mononuclear cells (PBMCs) of a healthy HLA-A2-negative donor. In the past, we have used the allorestricted approach to isolate high-avidity CTL specific for tumour-associated antigens. [30] [31] [32] However, we also demonstrated that the allorestricted repertoire displayed a wide range of functional avidities, which included low avidity CTL clones. 31 The allorestricted CTL line raised against LMP2 was peptide specific and efficiently bound to HLA-A2/LMP2 tetramers but did not recognize endogenous LMP2 expressed in lymphoblastoid cell line, consistent with a low functional avidity. (N Steven, S Lee, unpublished). These functional characteristics of the parental LMP2-specific T cell line were preserved upon TCR gene transfer.
The modified LMP2-TCR is functionally active
We analysed the peptide-specific killing activity of LMP2-TCR-transduced T cells using T2 target cells coated with LMP2 peptide or control peptide. Efficient killing was observed against T2 targets loaded with the relevant peptide but not the control peptide (Figure 3a) . Intracellular staining experiments were used to demonstrate that stimulation with LMP2 peptide, but not control peptide, resulted in interferon-g production by a large number of transduced T cells (Figures 3b and c) . A proportion of the interferon-g-positive cells also produced interleukin-2, and few cells produced only interleukin-2 and no interferon-g. The observation that LMP2-TCR-transduced T cells were able to produce cytokines in a peptide-specific manner was seen consistently using freshly transduced PBMC or T cell lines established from transduced PBMC.
Safety concerns related to mispairing of introduced TCR chains with endogenous chains recently led to the generation of modified human TCR constructs to facilitate the correct pairing. The introduction of two additional cysteine residues, capable of making an additional interchain disulfide bond or the replacement of the constant region with murine sequences both reduced mispairing with endogenous TCR chains and facilitated the pairing between modified chains. 26, 33, 34 In addition, it was observed that TCR constructs with murine constant region sequences associated with CD3 molecules more efficiently than full-length human TCR constructs. 26 We postulate that the combination of modifications used in this study, which endow the LMP2-TCR with dominance over endogenous TCR, will also minimize the potential mispairing in transduced cells. In addition, we produced a modified WT1-TCR that contained all modifications used in the LMP2-TCR plus an additional disulfide bond in the murine constant region. Cr-releaseÀspontaneous 51 Cr-release) Â 100). (b) PBMC transduced with the LMP2-TCR were analysed for intracellular IFNa and IL-2 production after stimulation with T2 target cells presenting an irrelevant control peptide or (c) the relevant LMP2 peptide (3 Â 10 13 transduced PBMC were stimulated with T2 cells loaded with relevant or irrelevant peptides at a 1:1 ratio in a roundbottom 96-well plate (TPP, Trasadingen, Switzerland). Brefeldin A, 1 mg ml À1 (Sigma, St Louis, MO, USA), was added after 2 h of stimulation. Cells were incubated for a further 18 h at 37 1C, 5% CO2, followed by surface staining, permeabilizing, fixing (Caltag, Burlingame, CA, USA) and intracellular staining as per manufacturer's recommendations). Shown are representative data from one experiment. More than three independent experiments were performed with similar results. Dominant TCR for gene therapy DP Hart et al TCR was suppressed in the majority of the transduced and peptide-expanded T cells. We found that the antihuman a/b-TCR antibody binds to an epitope in the constant region of the human b chain (data not shown). Thus, lack of antibody staining of the LMP2-TCR-transduced T cells indicates not only the absence of endogenous human a-/b-TCR, but also the absence of mispaired TCR consisting of endogenous b chain and introduced a chain. However, the presence of mispaired TCR consisting of endogenous a chain and introduced b chain cannot be excluded. Further experiments analysed LMP2-TCR-transduced cells at the earliest evaluable time point (48 h) posttransduction (Figures 4d and e) , demonstrating that approximately two-third of the LMP2-TCR-expressing cells were negative for the endogenous TCR, while approximately one-third of transduced T cells expressed both the LMP2-TCR as well as the endogenous TCR (Figure 4e ). These data indicated that LMP2-TCR dominance occurred in a large proportion of freshly transduced human T cells, and antigen stimulation resulted in the selective expansion of T cells expressing only the introduced TCR. We performed similar experiments with a version of the WT1-TCR that had the same modifications as the LMP2-TCR plus an additional disulfide bond between the murine constant regions. When this TCR was introduced into human T cells, approximately one-third of transduced T cells expressed both the introduced and endogenous TCR, while approximately two-third expressed only the introduced TCR (Figure 4f) . Again, peptide stimulation resulted in the preferential expansion of T cells expressing only the introduced WT1-TCR (Figure 4c ). Although all individual modifications used here were reported previously, we show here that the combined modifications produced TCR that were able to suppress the cell surface expression of the majority of endogenous TCR combinations in freshly transduced human T cells. The data also suggest that the introduction of an additional disulfide bond in the murine constant region of the modified WT1-TCR did not improve dominance compared with the modified LMP2-TCR, although this would need to be tested formally with disulfide bond negative/positive versions of the same TCR.
Dominance of the modified LMP2-TCR

Staining of transduced human T cells with antihuman
At present, the molecular mechanisms that underlie efficient TCR expression, and thus to determine TCR 'strength', are not known. Recent studies clearly indicated heterogeneity among human TCR, with some a/b combinations representing 'strong' TCR that were efficiently expressed, while others were inefficiently Figure 4 The modified LMP2-TCR and a modified Wilms'tumour antigen (WT1)-TCR are dominant over endogenous human TCR repertoire. Top row: (a) Bulk peripheral blood mononuclear cells (PBMC), transduced with the LMP2-TCR, were stained with antibodies specific for Vb13.1 and the constant b region of murine TCR or (b) with antibodies specific for the constant b region of murine TCR and the human a-/b-TCR, and analysed by flow cytometry. Analysis was performed after a single round of in vitro peptide stimulation (T2 cells and untransduced human leukocyte antigen-A2 positive PBMC feeders were incubated with peptide (100 mM) for 2 h, 37 1C and 5% CO 2 and then irradiated at 80 and 50 Gy, respectively. 5 Â 10 5 transduced T cells, 2 Â 10 5 T2 cells, 2 Â 10 6 feeder PBMC were plated out per well of a 24-well tissue culture plate (Nunc, Roskilde, Denmark) supplemented with 20 U ml À1 interleukin-2 (Chiron, USA)). (c) PBMC transduced with a modified WT1-TCR also underwent one round of peptide stimulation followed by staining with antibodies specific for the constant b region of murine TCR and human a-/b-TCR. The modifications in the WT1-TCR were identical to those made in the LMP2-TCR, except for an additional disulfide bond that was present in the murine constant region of the WT1-TCR. Bottom row: bulk PBMC transduced with the LMP2-TCR, analysed at 48 h after transduction, stained with (d) antibodies specific for Vb13.1 and the constant beta region of murine TCR or (e) antibodies specific for the constant beta region of murine TCR and human a-/b-TCR, and then analysed by flow cytometry. (f) Bulk PBMC were also transduced with the modified WT1-TCR and stained after 48 h with antibodies specific for the constant b region of murine TCR and human a-/b-TCR. All experiments shown were performed more than three times with similar results. Dominant TCR for gene therapy DP Hart et al expressed. 24, 25 The analysis of the small number of human T cells that still express endogenous TCR chains after transduction with the LMP2-TCR or WT1-TCR may provide some insight into molecular features of 'strong' TCR combinations. The sequence analysis of these endogenous chains may show amino-acid motifs that are common to 'strong' TCRs that continue to be expressed despite the presence of the introduced dominant TCR.
In addition to the vector and construct modifications described here, which improve surface LMP2-TCR expression and downregulate expression of endogenous TCRs, it may be possible to perform targeted mutagenesis of individual residues in the antigen-binding loops of this TCR to generate variants with subtle increments in binding affinity that may be able to recognize endogenous LMP2. This may overcome current limitations of random mutagenesis followed by in vitro selection of affinity-matured TCRs that have substantially increased biochemical binding affinities. Often, the transfer of these affinity-matured TCRs into T cells has not enhanced their functional avidity. 35 It is likely that subtle increments in TCR affinity (not exceeding the affinity range of 'natural' TCRs) or alterations in binding kinetics may correlate with increased functional avidity. The LMP2-TCR, with an affinity at the low end of the 'natural' range, will allow us to test this prediction experimentally.
The potential to engineer dominant TCR constructs is of major importance for TCR gene therapy to ensure optimal expression of the introduced TCR and reduce the autoimmunity risks arising from mispairing and from the activation of T cells expressing endogenous TCR with autoreactive specificity. We demonstrated that in vitro peptide stimulation efficiently enriched for T cells expressing only the introduced TCR, which would be expected to also occur in vivo when T cells encounter antigen. In contrast, the selective expansion of 'desired' T cells expressing only the introduced TCR may not happen when homoeostatic T-cell proliferation occurs in lymphopenic patients. Thus, the current lymphopeniainducing conditioning regiments may facilitate the persistence of 'undesired' T cells expressing introduced, mispaired as well as endogenous TCR.
Although we have clearly shown that TCR dominance can be achieved for the LMP2-TCR and the WT1-TCR, future studies using a large variety of TCR specificities are required to determine whether dominance can be achieved for any desired Va/Vb combination. It may be possible to exploit all tumour-reactive TCR, independent of their natural competitiveness for surface expression, for effective TCR gene therapy of human malignancies.
